Clinical Trial Update: Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating zanubrutinib, lenalidomide, and R-ICE in relapsed/refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Refractory

Drugs mentioned

• Lenalidomide (lenalidomide)
• R-ICE
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: RenJi Hospital | Conditions: Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | Phase 2 | Status: UNKNOWN